Back to Directory

Iris Mustich

Email

imustich@fhi360.org

Phone

919-627-6432

Institution

FHI 360

Title

Clinical Trials Specialist

Address

359 Blackwell St
Ste 200
Durham, NC 27701
United States of America

Request an Update

Affiliated Studies

IMPAACT 2034: Phase I Study of the Pharmacokinetics, Safety, and Acceptability of a Single Dose of Pretomanid Added to an Optimized Background Regimen in Children with Rifampicin-Resistant Tuberculosis

DAIDS Number

Research Area

Study Status

IMPAACT 2023: A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Dolutegravir in Neonates Exposed to HIV-1

DAIDS Number

Research Area

Study Status

IMPAACT 2019: Phase I/II Study of the Pharmacokinetics, Safety, and Tolerability of Abacavir/Dolutegravir/Lamivudine Dispersible and Immediate Release Tablets in HIV-1-Infected Children Less than 12 Years of Age

DAIDS Number

Research Area

Study Status

P1108: A Phase I/II, Open-Label, Single Arm Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Bedaquiline (BDQ) in Combination with Optimized Individualized Multidrug-Resistant Tuberculosis (MDR-TB) Therapy in HIV-Infected and HIV-Uninfected Infants, Children and Adolescents with MDR-TB Disease

DAIDS Number

Research Area

Study Status